<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478893</url>
  </required_header>
  <id_info>
    <org_study_id>SEL-068/101</org_study_id>
    <secondary_id>2011-003272-37</secondary_id>
    <nct_id>NCT01478893</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacodynamics of SEL-068 Vaccine in Smokers and Non-Smokers</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacodynamics of Increasing Subcutaneous Doses of SEL-068 in Healthy Non-Smoker and Smoker Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Selecta Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Selecta Biosciences, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacodynamics of SEL-068.
      Increasing subcutaneous doses of SEL-068 will be administered to healthy non-smoker and
      smoker volunteers. The resulting safety profile and anti-nicotine antibody levels will be
      evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of multiple subcutaneous injections of SEL-068 as assessed by frequency of vaccine related adverse events, graded by severity</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of SEL-068 by measuring anti-nicotine antibody titers by Enzyme-Linked Immunosorbent Assay (ELISA).</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>SEL-068</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SEL-068</intervention_name>
    <description>Sub-cutaneous injection, multiple dose</description>
    <arm_group_label>SEL-068</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Sub-cutaneous injection, multiple dose</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  Healthy Smokers

          -  Healthy non-smokers

          -  Written informed consent

        Primary Exclusion Criteria:

          -  Prior exposure to nicotine vaccines

          -  Female subjects of childbearing potential

          -  Current use of immunosuppressive agents

          -  History of or current autoimmune disorder of immunosuppressive condition (e.g. HIV
             infection)

          -  Concurrent participation or participation within 8 weeks prior to the initial study
             drug administration in a drug/device or biologic investigational research study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Vets, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SGS LSS Clinical Pharmacology Unit - Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS LSS Clinical Pharmacology Unit</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>January 5, 2016</last_update_submitted>
  <last_update_submitted_qc>January 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nicotine vaccine</keyword>
  <keyword>smoking vaccine</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>SEL-068</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

